# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

> **NCT01740791** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 103 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** Velpatasvir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01740791
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-06
- **Primary completion:** 2013-03-15
- **Final completion:** 2014-01-24
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740791, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01740791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*